Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT)
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie
PubMed
28533290
PubMed Central
PMC5561371
DOI
10.1136/annrheumdis-2016-210860
PII: S0003-4967(24)19820-2
Knihovny.cz E-zdroje
- Klíčová slova
- chondroitin sulfate, function, knee osteoarthritis, pain, treatment,
- MeSH
- artróza kolenních kloubů farmakoterapie patofyziologie MeSH
- celekoxib terapeutické užití MeSH
- chondroitinsulfáty terapeutické užití MeSH
- dvojitá slepá metoda MeSH
- inhibitory cyklooxygenasy 2 terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- měření bolesti MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- randomizované kontrolované studie MeSH
- Názvy látek
- celekoxib MeSH
- chondroitinsulfáty MeSH
- inhibitory cyklooxygenasy 2 MeSH
OBJECTIVES: Chondroitin sulfate 800 mg/day (CS) pharmaceutical-grade in the management of symptomatic knee osteoarthritis consistent with the European Medicines Agency guideline. METHODS: A prospective, randomised, 6-month, 3-arm, double-blind, double-dummy, placebo and celecoxib (200 mg/day)-controlled trial assessing changes in pain on a Visual Analogue Scale (VAS) and in the Lequesne Index (LI) as coprimary endpoints. Minimal-Clinically Important Improvement (MCII), Patient-Acceptable Symptoms State (PASS) were used as secondary endpoints. RESULTS: 604 patients (knee osteoarthritis) diagnosed according to American College of Rheumalogy (ACR) criteria, recruited in five European countries and followed for 182 days. CS and celecoxib showed a greater significant reduction in pain and LI than placebo. In the intention-to-treat (ITT) population, pain reduction in VAS at day 182 in the CS group (-42.6 mm) and in celecoxib group (-39.5 mm) was significantly greater than the placebo group (-33.3 mm) (p=0.001 for CS and p=0.009 for celecoxib), while no difference observed between CS and celecoxib. Similar trend for the LI, as reduction in this metric in the CS group (-4.7) and celecoxib group (-4.6) was significantly greater than the placebo group (-3.7) (p=0.023 for CS and p=0.015 for celecoxib), no difference was observed between CS and celecoxib. Both secondary endpoints (MCII and PASS) at day 182 improved significantly in the CS and celecoxib groups. All treatments demonstrated excellent safety profiles. CONCLUSION: A 800 mg/day pharmaceutical-grade CS is superior to placebo and similar to celecoxib in reducing pain and improving function over 6 months in symptomatic knee osteoarthritis (OA) patients. This formulation of CS should be considered a first-line treatment in the medical management of knee OA.
Department of Public Health Epidemiology and Health Economics Liège State University Liège Belgium
HFR Fribourg Hôpital Cantonal Fribourg Switzerland
Institute of Rheumatology Charles University Prague Czech Republic
Zobrazit více v PubMed
Arden N, Nevitt MC. Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol 2006;20:3–25.10.1016/j.berh.2005.09.007 PubMed DOI
Litwic A, Edwards MH, Dennison EM, et al. . Epidemiology and burden of osteoarthritis. Br Med Bull 2013;105:185–99.10.1093/bmb/lds038 PubMed DOI PMC
Hiligsmann M, Cooper C, Arden N, et al. . Health economics in the field of osteoarthritis: an expert’s consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum 2013;43:303–13.10.1016/j.semarthrit.2013.07.003 PubMed DOI
Hiligsmann M, Cooper C, Guillemin F, et al. . A reference case for economic evaluations in osteoarthritis: an expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum 2014;44:271–82.10.1016/j.semarthrit.2014.06.005 PubMed DOI
Jordan KM, Arden NK, Doherty M, et al. ; Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT). Ann Rheum Dis 2003;62:1145–55.10.1136/ard.2003.011742 PubMed DOI PMC
McAlindon TE, Bannuru RR, Sullivan MC, et al. . OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014;22:363–88.10.1016/j.joca.2014.01.003 PubMed DOI
Hochberg MC, Altman RD, April KT, et al. ; American College of Rheumatology. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012;64:465–74.10.1002/acr.21596 PubMed DOI
Bruyère O, Cooper C, Pelletier JP, et al. . An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO). Semin Arthritis Rheum 2014;44:253–63.10.1016/j.semarthrit.2014.05.014 PubMed DOI
Bruyère O, Cooper C, Pelletier JP, et al. . A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. Semin Arthritis Rheum 2016;45(4 Suppl):S3–S11.10.1016/j.semarthrit.2015.11.010 PubMed DOI
Cutolo M, Berenbaum F, Hochberg M, et al. . Commentary on recent therapeutic guidelines for osteoarthritis. Semin Arthritis Rheum 2015;44:611–7.10.1016/j.semarthrit.2014.12.003 PubMed DOI
Reginster JY, Cooper C, Hochberg M, et al. . Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis. Curr Med Res Opin 2015;31:1041–5.10.1185/03007995.2015.1027183 PubMed DOI
Bannuru RR, Schmid CH, Kent DM, et al. . Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med 2015;162:46–54.10.7326/M14-1231 PubMed DOI
Roberts E, Delgado Nunes V, Buckner S, et al. . Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis 2016;75:552–9.10.1136/annrheumdis-2014-206914 PubMed DOI PMC
da Costa BR, Reichenbach S, Keller N, et al. . Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet 2016;387:2093–105.10.1016/S0140-6736(16)30002-2 PubMed DOI
Martel-Pelletier J, Farran A, Montell E, et al. . Discrepancies in composition and biological effects of different formulations of chondroitin sulfate. Molecules 2015;20:4277–89.10.3390/molecules20034277 PubMed DOI PMC
Michel BA, Stucki G, Frey D, et al. . Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 2005;52:779–86.10.1002/art.20867 PubMed DOI
Kahan A, Uebelhart D, De Vathaire F, et al. . Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009;60:524–33.10.1002/art.24255 PubMed DOI
Uebelhart D, Thonar EJ, Delmas PD, et al. . Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage 1998;6(Suppl A):39–46.10.1016/S1063-4584(98)80011-3 PubMed DOI
Fransen M, Agaliotis M, Nairn L, et al. ; LEGS study collaborative group. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis 2015;74:851–8.10.1136/annrheumdis-2013-203954 PubMed DOI
Clegg DO, Reda DJ, Harris CL, et al. . Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006;354:795–808.10.1056/NEJMoa052771 PubMed DOI
Singh JA, Noorbaloochi S, MacDonald R, et al. . Chondroitin for osteoarthritis. Cochrane Database Syst Rev 2015;1:CD005614.10.1002/14651858.CD005614.pub2 PubMed DOI PMC
Reginster JY, Reiter-Niesert S, Bruyère O, et al. . Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes: expert consensus statement. Osteoarthritis Cartilage 2015;23:2086–93.10.1016/j.joca.2015.07.001 PubMed DOI
Altman R, Asch E, Bloch D, et al. . Development of criteria for the classification and reporting of osteoarthritis. classification of osteoarthritis of the knee. diagnostic and therapeutic criteria committee of the american rheumatism association. Arthritis Rheum 1986;29:1039–49. PubMed
Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957;16:494–502.10.1136/ard.16.4.494 PubMed DOI PMC
Lequesne MG. The algofunctional indices for hip and knee osteoarthritis. J Rheumatol 1997;24:779–81. PubMed
Tubach F, Ravaud P, Baron G, et al. . Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheum Dis 2005;64:29–33.10.1136/ard.2004.022905 PubMed DOI PMC
Tubach F, Ravaud P, Baron G, et al. . Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. Ann Rheum Dis 2005;64:34–7.10.1136/ard.2004.023028 PubMed DOI PMC
Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M, et al. . Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum 2007;56:555–67.10.1002/art.22371 PubMed DOI
Dieppe P, Goldingay S, Greville-Harris M. The power and value of placebo and nocebo in painful osteoarthritis. Osteoarthritis Cartilage 2016;24:1850–7.10.1016/j.joca.2016.06.007 PubMed DOI
Coste J, Montel S. Placebo-related effects: a meta-narrative review of conceptualization, mechanisms and their relevance in rheumatology. Rheumatology 2016:kew274.10.1093/rheumatology/kew274 PubMed DOI
Nguyen M, Dougados M, Berdah L, et al. . Diacerhein in the treatment of osteoarthritis of the hip. Arthritis Rheum 1994;37:529–36.10.1002/art.1780370413 PubMed DOI
Maheu E, Mazières B, Valat JP, et al. . Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month followup demonstrating a persistent effect. Arthritis Rheum 1998;41:81–91.10.1002/1529-0131(199801)41:1<81::AID-ART11>3.0.CO;2-9 PubMed DOI
Fidelix TS, Macedo CR, Maxwell LJ. Fernandes Moca Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev 2014;2:CD005117. PubMed PMC
Cohen J. Statistical power analysis for the behavioural sciences. 2nd Ed Hillsdale, NJ: Lawrence Earlbaum Associates, 1988.
